Daiichi Sankyo, Portola Expand Drug Pact in $33 Million Deal
By
Daiichi Sankyo has expanded its existing clinical collaboration agreement with Portola Pharmaceuticals, a South San Francisco-based biopharmaceutical company, to develop AndexXa (andexanet alfa) as an antidote for edoxaban, Daiichi Sankyo’s…
Aralez Completes Toprol-XL and Generic Acquisitions from AstraZeneca
By
Aralez Pharmaceuticals, a specialty pharmaceutical company headquartered in Mississauga, Ontario, Canada, has completed its acquisition of the US rights to Toprol-XL (metoprolol succinate) and its authorized generic, which are used…
Signal Genetics, Miragen to Merge for Micro-RNA Drugs
By
Signal Genetics, a Carlsbad, California- based commercial-stage molecular diagnostic company, and Miragen Therapeutics, a Boulder, Colorado-based privately-held biopharmaceutical company have entered into a definitive merger agreement under which the stockholders…